CancerNetwork, an arm of the prestigious journal Oncology, joined LFSA at the 7th International LFS Association Symposium to report on the latest advances in LFS research and clinical therapies. Reflected here are highlights of presentations by global experts.. Among them, Payal Khincha, MBBS, MSHS, shared a presentation on the progress of using metformin to
Presentations on advancements in early detection brought compelling research to light at the 7th International LFS Association Symposium. Trevor Pugh, PhD, FACMG, shared some early highlights from a randomized trial intended to assess the ability of cell-free DNA (cfDNA) sequencing to detect cancers in patients with LFS and similar cancer predisposition syndromes. Pugh is
The 7th International LFS Association Symposium delivered a powerful global collaboration intended to provide the best of care and hope to all of those with LFS and their families. In his talk on advancements in care, Michael J. Hall, MD, MS, FASCO, acknowledged how isolating it may be individuals receiving a diagnosis for LFS
A unique aspect of the LFSA International Symposium is the intersection of LFS families among globally renowned medical and scientific experts. Lisa J. States, MD, shared with CancerNetwork her insights and discussion take-aways around the goal of making whole body MRI scans less anxiety provoking for those with LFS. “We will work a
Another invitation to participate in a study about the risk-reducing mastectomy decision making process for adolescents and young adults with Li-Fraumeni Syndrome: A team of researchers at the Icahn School of Medicine at Mount Sinai are conducting a study to understand the factors that are most important to adolescents and young adults with Li-Fraumeni
LFSA founder Jenn Perry shares her family's LFS story and what motivates her to advocate for research and advancements to support those impacted by Li-Fraumeni syndrome. Jenn and her daughter Samantha were guests on WEEI's Gresh and Fauria show as part of the 2024 Jimmy Fund Radio - Telethon. They were helping to raise awareness
Li-Fraumeni syndrome (LFS) is a genetic disorder linked to mutations in the p53 tumor suppressor gene, leading to a wide range of cancers. While p53 mutations help explain some cancer risks, they don't fully account for the complex patterns seen in LFS. Recent research has found other genetic factors, like polymorphisms and telomere changes, that
Researchers analyzed families with a pattern of sarcomas, breast cancer, and other cancers occurring in young patients. They found that cancer developed in an autosomal dominant pattern, with 79% of affected individuals diagnosed before age 45. These families also had higher rates of brain tumors, leukemia, and adrenocortical carcinoma. The variety of cancers suggests unique
Researchers tested cells from people with Li-Fraumeni Syndrome (LFS), a genetic condition that increases cancer risk, to see how they respond to DNA-damaging agents like X-rays. They found no significant differences between the cells of affected individuals and those of unaffected relatives or controls, suggesting this method might not be useful for identifying at-risk
You are being invited to participate in a questionnaire study being run by Dana-Farber Cancer Institute. This study consists of a one-time questionnaire and is aimed at helping expand knowledge on breast cancer screening after mastectomy in women with Li-Fraumeni syndrome. You are eligible for this study if you: Are 18 years or older.
P.O. Box 6458
Holliston, MA 01746, USA
Phone: 1-833-4MYLFSA (1-833-469-5372)
Email: info@lfsassociation.org
© Copyright 2025 | Li-Fraumeni Syndrome Association | All Rights Reserved | Terms & Conditions | Privacy Policy
